You.com Announces Partnership with Boardwave To Bring AI-Powered Productivity To The European Software Industry
18.9.2024 10:00:00 CEST | Business Wire | Press release
You.com, an AI-powered productivity engine, and Boardwave, a prominent community for 1,700+ European software leaders, have today announced a joint partnership to accelerate productivity and the adoption of AI in the European software industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918041701/en/
You.com, an AI-powered productivity engine, and Boardwave, a prominent community for 1,700+ European software leaders, have today announced a joint partnership to accelerate productivity and the adoption of AI in the European software industry. (Graphic: Business Wire)
The new collaboration launches today at Boardwave Live in London and offers each of Boardwave’s members, and their leadership teams, access to You.com’s Team plan. This initiative equips European software entrepreneurs, founders, and CEOs with an all-in-one conversational AI platform for enhancing human productivity.
You.com offers access to the latest and most powerful Large Language Models (LLMs), enhanced with live web access. The platform features a range of powerful proprietary AI agents for research and problem-solving and the ability to create and share custom agents on top of any AI model for any task.
“Partnering with Boardwave is a great opportunity to get our AI into the hands of Europe’s software leaders. We’ve built You.com to tackle real productivity challenges. It’s not only about having the latest AI models; it’s about making them genuinely useful and trustworthy. Our APIs have been particularly popular in the SaaS community, allowing companies to integrate our AI capabilities directly into their workflows. We’re looking forward to partnering with Boardwave members to put these tools to work in their companies,” said Bryan McCann, CTO and co-founder of You.com, at the Boardwave Live event.
Boardwave Live is Boardwave’s Annual Conference, which draws together 450 of the best and brightest software Founders, CEOs, NEDs and Chairs from across Europe. During 2024, Boardwave has actively focussed on the use of “Practical AI” and how it can better support its community, using partnerships, events, mentorships and masterclasses. The partnership with You.com takes this to a deeper level and provides each of Boardwave’s members, and their executive teams, with access to all the popular LLMs.
“At Boardwave, we’re committed to accelerating the growth of European software companies. By partnering with You.com, we’re providing our members with access to an amazing toolkit of state-of-the-art AI, and all the major LLMS, that can significantly enhance their productivity. You.com’s offering includes access to all the latest AI models, best-in-class citations, reduced hallucinations, and improved accuracy, resulting in a more trustworthy experience. It’s a platform built by AI pioneers, and we’re excited to see how it will empower our community,” said Phill Robinson, CEO and co-founder of Boardwave.
For more information, visit www.you.com or www.boardwave.com.
For You.com’s APIs, visit https://you.com/business/api.
About You.com:
You.com is collaborative AI — for you, your team, and your business. You.com AI Agents maximize the productivity of knowledge workers through fast and accurate research and analysis, complex problem solving, content creation, and more. The company’s suite of APIs and end-to-end solutions drive revenue for businesses by becoming the foundation AI agent layer for their products and services. Founded by leading AI research scientists Richard Socher and Bryan McCann, You.com has raised $99 million from investors including Marc Benioff’s Time Ventures, Salesforce Ventures, NVIDIA, Gen Digital, SBVA, Georgian, Radical Ventures, Day One Ventures, Breyer Capital, Norwest Venture Partners, DuckDuckGo, Untapped Ventures, and others.
About Boardwave:
Boardwave is an impact-driven community of 1,700 European software founders and CEOs designed to help members accelerate their business growth, and to improve the overall position of Europe as a home for global software companies. Boardwave offers a programme of events, peer-to-peer mentoring and inspiration, as well as an online platform that connects European software CEOs for advice, insights, expertise and access to capital. It is also a campaigner for change across special interest areas including AI, Government engagement and DE&I. Software leaders, CEOs, NEDs and Chairs can access the programme and platform at no cost. The Boardwave community is generously supported and funded by a network of 85+ Partners from across the software investor and advisory ecosystem. www.boardwave.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20240918041701/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom